{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:25Z","timestamp":1747181125845,"version":"3.40.5"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,13]]},"abstract":"<jats:p>To explore the influence and effect of tumor microenvironment on the development of malignant mesothelioma using machine learning methods. 87 open cases were downloaded from the Cancer Genome Atlas database including transcriptome data, clinical data, and mutation data. The immune, stromal, and estimate scores were calculated for each case by using the ESTIMATE algorithm, and then the cases were grouped according to high and low stromal scores to predict all-cause survival in malignant mesothelioma cases. Their mutation data were analyzed to reveal the differences in mutated genes between the 2 groups, and then the von Willebrand factor (VWF) and FCRL3 genes were identified according to the intersection of DEGs and high-frequency mutated genes. Lastly, the correlation between VWF and the immune checkpoint of 22 kinds of immune cells was analyzed by using the CIBERSORT package of R software. A significant difference was found in the survival time of patients between the high and low stromal score groups. High expression of the VWF gene was negatively correlated with the prognosis of malignant mesothelioma, and the expression of VWF was positively correlated with naive B cells and activated CD4 memory T cells and negatively correlated with NK cells. The results revealed that high expression of VWF may involve in the development of malignant mesothelioma, and the anti-CTLA4 immune checkpoint treatment may have certain efficacy.<\/jats:p>","DOI":"10.1097\/md.0000000000035579","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:04:09Z","timestamp":1697231049000},"page":"e35579","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive bioinformatics analysis of the role of VWF in the tumor microenvironment of malignant mesothelioma"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2178-8764","authenticated-orcid":false,"given":"Jiren","family":"Weng","sequence":"first","affiliation":[{"name":"Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[{"name":"Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma.","volume":"353","author":"Robinson","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"e2120360","DOI":"10.1001\/jamanetworkopen.2021.20360","article-title":"Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017.","volume":"4","author":"Zhai","year":"2021","journal-title":"JAMA Network Open"},{"key":"R3-20250504","first-page":"383","article-title":"[Chinese guideline for clinical diagnosis and treatment of malignant pleural mesothelioma (2021 Edition)].","volume":"43","author":"Wang","year":"2021","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/gcc.22670","article-title":"Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes.","volume":"57","author":"Betti","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/ajcp\/86.2.227","article-title":"Pleural malignant mesothelioma following Wilms\u2019 tumor.","volume":"86","author":"Austin","year":"1986","journal-title":"Am J Clin Pathol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/1097-0142(19950801)76:3<437::AID-CNCR2820760314>3.0.CO;2-A","article-title":"Malignant pleural mesothelioma after radiation therapy for breast cancer. A report of two additional patients.","volume":"76","author":"Shannon","year":"1995","journal-title":"Cancer"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.ejcts.2007.12.024","article-title":"Pericardial malignant mesothelioma: a latent complication of radiotherapy?","volume":"33","author":"Small","year":"2008","journal-title":"Eur J Cardiothoracic Surg"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/cncr.22526","article-title":"Therapeutic radiation for lymphoma: risk of malignant mesothelioma.","volume":"109","author":"Teta","year":"2007","journal-title":"Cancer"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.5858\/arpa.2014-0569-OA","article-title":"Malignant (Diffuse) mesothelioma in patients with hematologic malignancies: a clinicopathologic study of 45 cases.","volume":"139","author":"Li","year":"2015","journal-title":"Arch Pathol Laboratory Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1200\/JCO.1983.1.11.695","article-title":"Malignant mesothelioma following radiation exposure.","volume":"1","author":"Antman","year":"1983","journal-title":"J Clin Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/1097-0142(19850715)56:2<273::AID-CNCR2820560212>3.0.CO;2-0","article-title":"Malignant pleural mesothelioma following radiotherapy in a 16-year-old boy.","volume":"56","author":"Anderson","year":"1985","journal-title":"Cancer"},{"issue":"Suppl 5","key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1289\/ehp.97105s51061","article-title":"Oncogenes and tumor-suppressor genes in mesothelioma \u2013 a synopsis.","volume":"105","author":"Lechner","year":"1997","journal-title":"Environ Health Perspect"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000109618","article-title":"Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH.","volume":"119","author":"Lindholm","year":"2007","journal-title":"Cytogenet Genome Res"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cancergencyto.2006.04.011","article-title":"Cytogenetic and molecular genetic changes in malignant mesothelioma.","volume":"170","author":"Musti","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1002\/eji.201444594","article-title":"Natural killer and dendritic cells collaborate in the immune response induced by the vaccine against uterine cervical cancer.","volume":"44","author":"Langers","year":"2014","journal-title":"Eur J Immunol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygyno.2018.01.014","article-title":"Tumor associated macrophages in gynecologic cancers.","volume":"149","author":"Krishnan","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fonc.2019.01366","article-title":"The immune microenvironment in mesothelioma: mechanisms of resistance to immunotherapy.","volume":"9","author":"Chu","year":"2019","journal-title":"Front Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e106742","DOI":"10.1371\/journal.pone.0106742","article-title":"Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.","volume":"9","author":"Cornelissen","year":"2014","journal-title":"PLoS One"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/PPO.0000000000000127","article-title":"The role of stroma in tumor development.","volume":"21","author":"Werb","year":"2015","journal-title":"Cancer J"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/JTO.0b013e3181f8a1bd","article-title":"The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer.","volume":"6","author":"Bremnes","year":"2011","journal-title":"J Thoracic Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data.","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-18-4093","article-title":"Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to drive the development of pleural malignant mesothelioma in conditional mouse models.","volume":"79","author":"Kukuyan","year":"2019","journal-title":"Cancer Res"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.annepidem.2017.04.001","article-title":"Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis.","volume":"27","author":"Mezei","year":"2017","journal-title":"Ann Epidemiol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"R25-20250504","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","article-title":"British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma.","volume":"73","author":"Woolhouse","year":"2018","journal-title":"Thorax"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.02.021","article-title":"Progress in the Management of Malignant Pleural Mesothelioma in 2017.","volume":"13","author":"McCambridge","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"934","DOI":"10.21037\/tlcr-2019-pps-10","article-title":"Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma.","volume":"9","author":"Hjerpe","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bjc.2015.286","article-title":"Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.","volume":"113","author":"Kirschner","year":"2015","journal-title":"Br J Cancer"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1471-2407-13-205","article-title":"Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.","volume":"13","author":"Tabata","year":"2013","journal-title":"BMC Cancer"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1136\/thoraxjnl-2021-217709","article-title":"Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study.","volume":"77","author":"van Kooten","year":"2022","journal-title":"Thorax"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-319-78127-3_6","article-title":"Stromal cells in the tumor microenvironment.","volume":"1060","author":"Denton","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/MBC.0b013e32834cb35d","article-title":"Structure and function of von Willebrand factor.","volume":"23","author":"Hassan","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.thromres.2013.01.015","article-title":"von Willebrand factor and cancer: a renewed interest.","volume":"131","author":"Franchini","year":"2013","journal-title":"Thromb Res"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"e2013060","DOI":"10.4084\/mjhid.2013.060","article-title":"Von Willebrand factor, angiodysplasia and angiogenesis.","volume":"5","author":"Randi","year":"2013","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"110517","DOI":"10.18632\/oncotarget.22806","article-title":"GATA3-induced vWF upregulation in the lung adenocarcinoma vasculature.","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00428-004-1051-z","article-title":"Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer.","volume":"445","author":"Lackner","year":"2004","journal-title":"Virchows Arch"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1111\/jth.15773","article-title":"The role of VWF\/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.","volume":"20","author":"Comerford","year":"2022","journal-title":"J Thromb Haemost"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2010-01-264507","article-title":"Endothelial von Willebrand factor regulates angiogenesis.","volume":"117","author":"Starke","year":"2011","journal-title":"Blood"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection.","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy.","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3389\/fimmu.2019.02278","article-title":"NK cell metabolism and tumor microenvironment.","volume":"10","author":"Terr\u00e9n","year":"2019","journal-title":"Front Immunol"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the treatment of malignant pleural mesothelioma.","volume":"385","author":"Janes","year":"2021","journal-title":"N Engl J Med"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"e1494111","DOI":"10.1080\/2162402X.2018.1494111","article-title":"Combination immune checkpoint blockade as an effective therapy for mesothelioma.","volume":"7","author":"Fear","year":"2018","journal-title":"Oncoimmunology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:12:42Z","timestamp":1746324762000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":43,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035579","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}